(Reuters) – Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.
(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
Sangamo to reclaim hemophilia A therapy rights post Pfizer termination
Dec 30, 2024 | 5:15 PM
On Air Now
Thu Nov 5
Holland, MI, USA
54°FWind/Dir: 30 MPH-SW
Humidity: 77%
Our Playlist
Comments